Hers Weight Loss vs Hims Weight Loss for Women 2026: Which Is Better?

Affiliate disclosure: BestMedsHub may earn a commission when you sign up through links on this page. Our editorial recommendations are independent and based on clinical evidence, pricing transparency and verified user feedback. Last updated May 2026.

Hims & Hers Health is one of the largest telehealth platforms in the United States, and its weight loss program is among the most aggressively marketed in the country. But the brand operates two front-end storefronts: Hers Weight Loss, marketed to women, and Hims Weight Loss, marketed to men. They share infrastructure, prescribers and supply chain — but the consumer experience, the educational content and the way each platform handles women’s metabolic health are not identical.

This 2026 head-to-head compares Hers vs Hims weight loss specifically through the lens of women’s metabolic care: PCOS, perimenopause, hormonal weight gain, breastfeeding contraindications, GLP-1 access after the FDA’s September 2025 compounding crackdown, and which storefront — if either — is the better fit for female patients.

Hers vs Hims Weight Loss 2026: At-a-Glance Comparison

Hers Weight Loss Deep Dive 2026

Hers Weight Loss is the women-facing storefront for the Hims & Hers metabolic program. The clinical pathway is built on the company’s nationwide telehealth prescriber network — a mix of MDs and nurse practitioners — and centers on an asynchronous intake: members complete a detailed medical history questionnaire, upload labs if required, and a licensed prescriber in their state reviews and writes a prescription, typically within 24-48 hours.

What distinguishes Hers from Hims is mostly the content layer. Hers operates dedicated educational hubs on PCOS, perimenopause, postpartum recovery and hormonal weight gain — topics that are real drivers of female metabolic health and that the male-facing Hims storefront covers more briefly. The intake flow includes prompts about menstrual cycle regularity, recent pregnancy and hormonal contraceptive use, which feed into the prescriber’s clinical review.

On medications, Hers offers the same toolkit available across the platform: compounded semaglutide at roughly $199-$299/month, FDA-approved Wegovy and Zepbound as add-on options at variable cost, and a range of oral options including metformin, naltrexone-bupropion (Contrave) and topiramate kits. The compounded semaglutide pathway is the most affordable and the most marketed, but it sits in a post-crackdown FDA gray area we will unpack below.

The visit experience is primarily async messaging. Hers does offer scheduled video visits in some states, but the default model is questionnaire + asynchronous prescriber review + messaging follow-up. This is faster and cheaper than synchronous obesity medicine care, but it is also less clinically deep — there is no dedicated obesity medicine specialist on your case, and your prescriber may rotate.

Hims Weight Loss Deep Dive 2026

Hims Weight Loss is the male-facing twin of the same program. The pricing is identical: roughly $79/month for the metabolic program, $199-$299/month for compounded semaglutide, and variable add-on pricing for Wegovy and Zepbound. The prescriber network, supply chain and app infrastructure are shared.

Where Hims differs is in marketing and content focus. The educational content centers on testosterone, male metabolic syndrome, visceral fat and cardiovascular risk reduction — topics relevant to the male audience but less applicable to female users. For a woman comparing the two, choosing Hims over Hers gets you the same prescription with less relevant educational scaffolding.

For the small subset of women whose physician has already determined that hormonal considerations are not in play — for example, post-menopausal women not on hormone replacement therapy, with no PCOS history and no breastfeeding concerns — the choice between Hers and Hims is functionally cosmetic. The clinical experience and medication access are the same.

Pricing Breakdown 2026

Hers and Hims pricing is functionally identical. The differentiator is which medication pathway you take.

Hers / Hims 2026 Pricing

• Metabolic program (no GLP-1): ~$79/month, includes provider access, basic coaching content and oral medications if prescribed
• Compounded semaglutide: ~$199-$299/month depending on dose and subscription length (annual plans are cheaper per month)
• Compounded tirzepatide (where available): ~$299-$499/month
• Wegovy (FDA-approved): variable; ~$499-$1,349/month at cash pricing through Novo Nordisk direct, no insurance billing through Hers/Hims
• Zepbound (FDA-approved): variable; ~$499-$1,059/month for vials through Lilly direct
• NOT included: insurance billing, labs (typically must be done independently), specialist referrals, in-person care

Manufacturer savings card eligibility on Wegovy and Zepbound applies only when prescriptions are billed through commercial insurance. Hers and Hims operate cash-pay, so most savings card pathways do not apply to FDA-approved GLP-1s purchased through the platform.

Medication Access in 2026

The 2026 medication landscape is shaped by the FDA's September 2025 compounding crackdown. When the FDA officially declared the semaglutide and tirzepatide shortages resolved, the legal basis for mass-market compounded GLP-1s narrowed sharply. Under FDA Section 503A and 503B guidance, compounded versions are now legal only as personalized formulations — for example, a documented allergy to an inactive ingredient in the commercial product, a non-commercially-available dose strength prescribed for clinical reasons, or a different route of administration.

In plain English: a compounded semaglutide formulation that adds B12 or pyridoxine and is prescribed because a patient's chart documents a clinical reason for the personalization is generally on the legal side of the line. A compounded semaglutide that is functionally identical to commercial Wegovy and prescribed in bulk through a questionnaire is in a much grayer area.

Hers and Hims publicly position their compounded GLP-1 offerings as personalized formulations. Whether your specific prescription qualifies depends on the documentation in your chart. As a buyer's protection lens — not legal advice — you should:

• Ask your prescriber explicitly what clinical reason justifies the compounded formulation in your case
• Confirm the compounding pharmacy is a registered 503A or 503B facility (Hers/Hims uses both)
• Ask for documentation of the active ingredient source and sterility testing
• Understand that compounded products do not carry the same FDA labeling and post-market safety surveillance as commercial Wegovy or Zepbound

FDA-approved Wegovy and Zepbound remain available through Hers and Hims as add-on prescriptions, with no compounding ambiguity, but at substantially higher cost without insurance billing.

Doctor Quality and Ongoing Care

Hers and Hims operate an async-first prescriber model. The default experience is: complete a detailed intake questionnaire, upload medical history, get reviewed by a state-licensed MD or NP, and receive a prescription within 24-48 hours. Follow-up is via asynchronous messaging through the app.

Prescribers are state-licensed and credentialed, but they are not generally board-certified in obesity medicine. They are part of a nationwide telehealth network and your assigned prescriber may rotate over the course of your subscription. This is functionally different from Form Health or Calibrate, where you typically work with the same obesity medicine specialist over months.

For straightforward weight loss cases — an otherwise healthy adult with a clear BMI indication and no complicating conditions — the async model is fast, accessible and effective. For complex cases involving PCOS, perimenopause, postpartum recovery, thyroid disease or psychiatric medication interactions, the async model is less well-suited and a dedicated obesity medicine specialist may serve you better.

Women-Specific Considerations: PCOS, Perimenopause, Hormonal Weight Gain and Breastfeeding

This is the section that matters most if you are a woman comparing Hers and Hims. The female metabolic experience differs from the male experience in ways that a generic weight loss program does not always address.

PCOS

Polycystic ovary syndrome affects an estimated 8-13% of reproductive-age women and is strongly associated with insulin resistance, weight gain and difficulty losing weight. GLP-1 medications including semaglutide have shown promising results in PCOS, with peer-reviewed studies in 2024-2025 documenting improvements in insulin sensitivity, menstrual regularity and weight loss. Metformin remains a first-line pharmacotherapy for PCOS-related metabolic dysfunction and is available through both Hers and Hims.

If you have PCOS, Hers' women-focused intake is more likely to surface the diagnosis and route you toward appropriate medications. However, complex PCOS cases — particularly those involving fertility planning, severe insulin resistance or comorbid endometrial concerns — typically benefit from a reproductive endocrinologist or an ABOM-certified obesity medicine physician rather than an async telehealth program.

Perimenopause and Menopause

Perimenopausal weight gain is real and is driven by hormonal shifts that begin in the late 30s to mid-40s. Estrogen decline alters fat distribution toward central adiposity, and metabolic rate decreases independently of dietary change. GLP-1 therapy can be effective in this population, but interactions with hormone replacement therapy (HRT) require clinical attention.

Hers surfaces perimenopause-related content more prominently than Hims. Neither program, however, is purpose-built for menopause care, and women who are actively on HRT or considering it should consult a menopause specialist alongside any GLP-1 prescription.

Hormonal Weight Gain Beyond Reproductive Causes

Thyroid disorders, cortisol dysregulation and prolactin-elevating medications can all drive weight gain that is not primarily caloric. GLP-1s do not address these root causes. A comprehensive workup — TSH, free T4, morning cortisol, prolactin — is appropriate before assuming a weight gain pattern is diet-driven. Hers and Hims do not typically order this workup as part of intake; you may need labs from a primary care physician first.

Breastfeeding Contraindications

This is non-negotiable: GLP-1 medications including Wegovy, Zepbound, Saxenda, Ozempic and Mounjaro are not recommended during pregnancy or breastfeeding. The FDA labels for these medications advise discontinuation prior to a planned pregnancy and indicate insufficient safety data for breastfeeding infants. Compounded versions carry the same biological cautions even if the labeling differs.

If you are pregnant, trying to conceive within 2-3 months, or actively breastfeeding, you should not be on a GLP-1 medication. Both Hers and Hims screen for pregnancy and breastfeeding in intake, but the responsibility ultimately rests with the patient to disclose accurately.

Hormonal Contraception

GLP-1 medications can theoretically affect absorption of oral contraceptives during the rapid gastric emptying phase of treatment. Backup contraception during dose escalation is reasonable, and the FDA Mounjaro label specifically advises this. Hers' intake is more likely to surface this consideration than Hims.

Who Each Program Is Best For

Hers Weight Loss Is Best For:

• The convenience-prioritizing woman with straightforward weight loss goals. Someone with no significant hormonal complexity who values fast async access, lower price points and women-focused educational content.
• The PCOS-aware patient seeking metformin or oral options first. Someone who suspects insulin resistance is part of the picture and wants a quick path to metformin or naltrexone-bupropion without a long primary care wait.

Hims Weight Loss Is Best For:

• The post-menopausal woman with no hormonal complexity. Someone for whom the women-focused content on Hers offers little additional value and who prefers the simpler male-marketed funnel.
• The price-sensitive shopper comparing identical infrastructure. Someone who has already determined the clinical pathway and is choosing the storefront with the most convenient ongoing subscription experience.

Customer Feedback Patterns

Pulling themes from Reddit (r/HersWeightLoss, r/Semaglutide, r/loseit) and Trustpilot in early 2026:

Hers themes: Members praise the speed of intake, the low entry price and the women-focused content. Common complaints involve provider rotation, difficulty escalating to a synchronous video visit when needed, and confusion about the compounded vs FDA-approved medication pathways.

Hims themes: Similar pattern — fast access, low entry price, but limited specialist depth. Trustpilot reviews frequently reference shipping delays for compounded medications during peak demand periods.

Across both storefronts, the most consistent caution from users is that this is a high-volume telehealth product, not a specialist obesity clinic. Patients who treat it as such — and who treat their primary care physician as the home base for complex care — tend to report better experiences.

Frequently Asked Questions

Is Hers Weight Loss actually different from Hims Weight Loss?

The clinical infrastructure, prescriber network and medications are the same. The differences are in marketing, intake questions and educational content, with Hers offering more women-focused material on PCOS and perimenopause.

Does Hers or Hims take insurance?

No. Both are cash-pay platforms. Manufacturer savings cards for Wegovy and Zepbound generally require insurance billing and do not apply to cash-pay prescriptions through Hers/Hims.

Is the compounded semaglutide from Hers safe in 2026?

Hers uses registered 503A and 503B compounding pharmacies and positions its compounded GLP-1s as personalized formulations under FDA guidance. Compounded medications do not carry the same FDA labeling and post-market surveillance as commercial Wegovy. Ask your prescriber to document the clinical reason for the personalized formulation.

Can I get Wegovy or Zepbound through Hers?

Yes, both are available as add-on prescriptions, but typically at cash pricing of ~$499-$1,349/month with no insurance billing through the platform.

Is Hers safe for women with PCOS?

Hers can prescribe metformin and GLP-1s, which are both used in PCOS metabolic management. However, complex PCOS — particularly fertility-related cases — typically warrants a reproductive endocrinologist alongside any weight loss prescription.

Can I use Hers while breastfeeding?

No. GLP-1 medications are not recommended during breastfeeding, and Hers/Hims screen for this in intake. Some non-GLP-1 oral options may be considered case-by-case but most weight loss pharmacotherapy is contraindicated.

What if I have a thyroid condition?

Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are contraindications for GLP-1 therapy. Hypothyroidism is not a contraindication but should be well-controlled before starting weight loss medication.

Is Hers a good fit for perimenopausal weight gain?

It can be, but for women on hormone replacement therapy or actively navigating menopause symptoms, a menopause specialist alongside any GLP-1 prescription is the more comprehensive approach.

Final Verdict: Hers vs Hims Weight Loss for Women 2026

Choose Hers if: you are a woman seeking weight loss care through a high-volume telehealth platform, you value women-focused educational content, and your case is relatively straightforward without major hormonal complexity. Hers' intake and content are better suited to female metabolic health.

Choose Hims if: you are a post-menopausal woman with no hormonal complexity, you have already determined your clinical pathway, and you simply prefer the male-marketed storefront's interface. Functionally, you are getting the same prescription.

Consider an alternative if: you have complex PCOS, are perimenopausal on HRT, are breastfeeding or recently postpartum, have a complicated psychiatric medication regimen, or want a board-certified obesity medicine specialist on your case. In those situations, a dedicated obesity medicine practice or a program like Form Health (insurance-first) or Calibrate (year-long structured) is likely the better fit.

For most women in 2026, Hers Weight Loss is a reasonable, affordable entry point into medical weight loss — provided you go in with clear eyes about the async-first model and the compounded-vs-FDA medication landscape.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications including Wegovy, Zepbound, Saxenda, Ozempic and Mounjaro carry boxed warnings and contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, breastfeeding and severe gastrointestinal disease. Compounded medications do not carry the same FDA labeling and post-market surveillance as commercial products. Always consult a licensed physician before starting any prescription weight loss program. Pricing is accurate to the best of our knowledge as of May 2026 and is subject to change.

Affiliate disclosure: BestMedsHub maintains affiliate relationships with both Hers Weight Loss and Hims Weight Loss. When you click a link on this page and sign up, we may receive a commission at no additional cost to you. These relationships do not influence our editorial rankings, which are based on independent review of clinical credentialing, pricing transparency, FDA compliance and verified customer feedback patterns. We do not accept payment for favorable reviews.